PatientsVille.com Logo


Esophageal Medical Research Studies

Up-to-date List of Esophageal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Esophageal Medical Research Studies

Rank Status Study
1 Recruiting WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Condition: Refractory Anastomotic Esophageal Strictures
Interventions: Device: WallFlex Esophageal RX Fully Covered Stent;   Device: Esophageal Bougie Dilator Per Investigator preference
Outcome Measures: Number of procedures;   Technical stent placement success defined as the ability to deploy the stent in satisfactory position across the stricture;   Technical stent removal success defined as the ability to remove the stent without complications.;   Patient's satisfaction with therapy;   Patient's report of pain;   Quality Of Life (QOL): Improvement in EQ-5D-5L;   Patient diary to assess dysphagia scores;   Health Economic Endpoint;   Title: Health Economic Endpoint;   Safety Endpoint;   Efficacy Endpoint
2 Not yet recruiting EndoMAXX EVT Fully Covered Esophageal Stent With Valve Compared to the EndoMAXX EVT Fully Covered Esophageal Stent for Malignant Strictures Requiring Stent Placement Across the GastrOesophageal Junction
Condition: Malignant Cancer of the Esophagus
Interventions: Device: EndoMAXX Fully Covered Esophageal Stent with Valve;   Device: EndoMAXX Fully Covered Esophageal Stent
Outcome Measures: Mellow and Pinkas Dysphagia Score;   GERD-HRQL;   Regurgitation Questionnaire;   Safety
3 Recruiting Removal of the Evolution® Esophageal Stent - Fully Covered
Conditions: Esophageal Fistula;   Esophageal Neoplasms;   Esophageal Perforation;   Esophageal Stenosis;   Stents
Intervention: Device: Evolution® Esophageal Stent - Fully Covered
Outcome Measures: Successful removal of study stent;   Clinical success;   Dysphagia;   Incidence of procedural- and/or device-related adverse events;   Incidence of stent removal-related adverse events;   Device integrity during the stent removal procedure;   Technical success
4 Unknown  a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent
Condition: Esophageal Cancer
Interventions: Device: novel stent;   Device: conventional covered stent
Outcome Measures: Overall survival and Median Survival;   Quality of life [ECOG performance status],Dysphagia grade [STOOLER stand],Change of the Oesophageal cancer [ RECIST standard],Restenosis degree[esophagus visualization];   Pathologic change of the cancer;   Successful rate of stent placement
5 Unknown  Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children
Conditions: Esophageal Stricture;   Caustic Esophageal Stricture;   Peptic Esophageal Stricture;   Post-Surgical Esophageal Stricture
Intervention: Drug: Mitomycin C
Outcome Measures: Number of days with improved symptom (dysphagia) after dilation session.;   Esophageal diameter
6 Recruiting Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital
Conditions: Esophageal Cancer;   Esophageal Squamous Dysplasia
Interventions: Procedure: Endoscopic Mucosal Resection (EMR);   Device: Radiofrequency ablation
Outcome Measures: Complete resolution of advanced esophageal squamous dysplasia;   Safety of endoscopic interventions
7 Recruiting Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.
Conditions: Esophageal Varices;   Bleeding;   Cirrhosis
Interventions: Device: Stent;   Device: Tamponade
Outcome Measures: Combined: bleeding + absence of severe adverse events + survival;   Bleeding;   Survival;   Transfusional requirements;   Adverse events;   Analgesia and sedation requirements;   Hospital stay;   Applicability of definitive hemostatic therapy.
8 Unknown  Effect of Azithromycin on Oesophageal Hypomotility
Condition: Esophageal Motility Disorders
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Effect of Azithromycin on Oesophageal peristalstic contraction amplitude in patients with hypomotility;   Manometric Oesophageal body response (amplitude of peristaltic contractions in mmHg and also Distal Contractal Integral in mmHg.cm.second) to solid bolus swallows, MRS and outlet obstruction in healthy subjects and patients with Oesophageal hypomotility.
9 Not yet recruiting Esophageal Fully Covered Metal Stents in Caustic Strictures Study
Condition: Refractory Benign Esophageal Strictures Caused by Caustic Ingestion
Intervention: Device: Metal Stent (WallFlex™ Esophageal RX)
Outcome Measures: Clinical success consisting of stent tolerability and adequate ability to sustain nutrition to 6 months after stent removal.;   Technical stent placement success defined as the ability to deploy the stent in satisfactory position across the stricture.;   Stent removal success defined by the ability to remove the stent endoscopically without stent removal related complications.;   Stent tolerability defined as completion of planned stent indwell.;   Patient's Report on Pain compared to Baseline: Day 2, week 1, week 2, and thereafter every 2 weeks until stent removal.;   Change of pain medication intake from Baseline: Day 2, week 1, week 2, and thereafter every 2 weeks until stent removal.;   Improvement of dysphagia score compared to Baseline: Day 2, week 1, week 2, and thereafter every 2 weeks until end of study.;   Dysphagia score during stent treatment compared to dysphagia score during preceding Standardized Esophageal Caustic Stricture Endoscopic Treatment Regimen (SECSER).;   Quality Of Life (QOL) Improvement compared to Baseline: Day 2, week 1, week 2, and thereafter every 2 weeks until end of study.;   Occurrence and severity of adverse events related to the stent and/or the stent placement or stent removal procedure and of all serious adverse events throughout the duration of the study.;   Time to recurrence of stricture, defined as inability of a normal diameter gastroscope (9.8 mm) to pass the stricture.;   Incidence of stent migration with or without related Adverse Events (AE).;   Health Economic Endpoint;   Improvement in Patient Weight compared to Baseline: Day 2, week 1, week 2, and thereafter every 2 weeks until end of study.;   Weight gain during stent treatment compared to weight gain during preceding SECSER.
10 Recruiting Esophageal Cancer Risk Registry
Conditions: Esophageal Cancer;   GastrOesophageal Reflux Disease;   Esophageal Diseases;   Hiatal Hernia;   Esophageal Achalasia
Interventions: Procedure: Survey of client health, personal habits, family history;   Procedure: Blood specimen for non-DNA and DNA parts;   Procedure: Biopsy of esophageal/stomach tissue, lymph nodes, tumor;   Procedure: Biopsies from routine clinical surveillance endoscopies
Outcome Measure:
11 Recruiting RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage
Condition: Acute Bleeding Esophageal Varices
Interventions: Device: Self-expanding mesh-metal Oesophageal stent (SEMS);   Other: Standard Therapy
Outcome Measures: Failure to Control Bleeding;   Absence of Bleeding at 14 and 42 days;   Participant Survival;   Absence of Stent Migration;   Requirement for Blood products;   Requirement for Analgesia and Sedation whilst Stent in in situ;   Presence of Thoracic Pain or Dysphagia;   Length of Intensive Care Unit and Total Hospital Stay;   Requirement for additional endoscopic therapy or salvage therapy (such as TIPS);   Repeated presentation with variceal bleeding within 6 months
12 Recruiting Deviating the Esophagus in Atrial Fibrillation Ablation
Conditions: Esophageal Deviation;   Atrial Fibrillation;   Ablation
Intervention: Procedure: esophageal deviation
Outcome Measures: presence of esophageal injury;   Esophageal deviation;   Temperature;   Swallowing impairment score
13 Unknown  Open or Keyhole Surgery Through the Chest for Newborn Babies: Effect on Blood Gases
Conditions: Esophageal Atresia With Tracheo-esophageal Fistula;   Congenital Diaphragmatic Hernia
Interventions: Procedure: Hypercapnia during thoracoscopy;   Procedure: Open surgery
Outcome Measures: Arterial blood carbon dioxide measurement;   oxygenation of the brain;   arterial carbon dioxide levels measured transcutaneously
14 Recruiting Esophageal Stump Washout
Conditions: Esophageal Cancer;   Cancer of the Gastro-esophageal Junction
Intervention: Procedure: Esophageal Stump Washout
Outcome Measure: Presence of intraluminal tumor cells in the remaining Oesophageal stump
15 Recruiting Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
Condition: Esophageal Stricture
Intervention: Drug: Budesonide
Outcome Measures: Dysphagia score;   recurrence of esophageal stricture
16 Unknown  Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring
Condition: Esophageal Motility Disorders
Outcome Measure:
17 Recruiting Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Conditions: Esophageal Cancer;   Neoplasms, Esophageal
Interventions: Drug: Everolimus;   Drug: Paclitaxel;   Drug: carboplatin;   Drug: cetuximab
Outcome Measures: Phase II to assess the rate of pathologic CR in patients with resectable esophageal carcinoma receiving induction therapy followed by surgical resection;;   Phase I portion to determine the Maximum tolerated dose MTD and dose limiting toxicity DLT of RAD001 in combination with radiation;   Rate of surgical pathologic complete remission pCR (absence of evidence of cancer after surgery)
18 Recruiting Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
Conditions: Bleeding Esophageal Varices;   Hepatocellular Carcinoma
Interventions: Drug: Propranolol;   Procedure: Esophageal variceal ligation
Outcome Measures: Bleeding;   Complication survival
19 Unknown  A Trial of Esophageal and Gastric Stenting for Leak or Perforation
Conditions: Esophageal or Gastric Perforations;   Esophageal or Gastric Leaks
Intervention: Device: Boston Scientific Ultraflex or Wallstent stents
Outcome Measures: Safety of esophageal stenting by conducting an Omnipaque swallow and by the success of leakage stops and fistula healing.;   Efficacy of esophageal stenting by the success of leakage stops and fistula healing.;   A 30 day duration of stent placement and the relation to the healing esophagus;   An institutional protocol for stent management
20 Recruiting Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
Conditions: Esophageal Cancer;   Esophageal Stenosis
Interventions: Device: Partially covered SEMS;   Device: Fully covered SEMS
Outcome Measures: Recurrent dysphagia.;   Technical success of SEMS placement;   Clinical success defined as improvement of dysphagia score;   Major and minor complication rate;   Quality of Life;   Survival

These studies may lead to new treatments and are adding insight into Esophageal etiology and treatment.

A major focus of Esophageal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Esophageal